Skip to main content

Table 2 Associations between metformin use at hospital admission for AMI and MACE over median follow-up of 343 (IQR: 1–1436) days

From: Metformin use and cardiovascular outcomes after acute myocardial infarction in patients with type 2 diabetes: a cohort study

 Number of patients experiencing event (%)UnadjustedAdjusteda
Metformin (N = 2576)Other (N = 1454)Hazard ratio (95% CI)P valueHazard ratio (95% CI)P value
Primary endpoint
 MACE (composite of cardiovascular mortality, AMI and stroke)1551 (60.2)899 (61.8)0.95 (0.88–1.03)0.2391.09 (1.01–1.19)0.034
Components of primary endpoint
 Cardiovascular mortality894 (34.7%)584 (40.2%)0.84 (0.76–0.93)0.0011.06 (0.96–1.17)0.275
 AMI807 (31.3%)433 (29.8%)1.01 (0.90–1.14)0.8871.06 (0.94–1.20)0.363
 Stroke294 (11.4%)195 (13.4%)0.84 (0.70–1.00)0.0510.99 (0.82–1.19)0.904
Secondary endpoints
 All-cause mortality1423 (55.2%)1020 (70.2%)0.77 (0.71–0.83)< 0.0010.97 (0.89–1.04)0.395
 HF hospitalisation589 (22.9)313 (21.5)1.01 (0.88–1.16)0.9181.13 (0.98–1.30)0.092
  1. AMI acute myocardial infarction, HF heart failure
  2. aAdjusted for: age at index AMI, sex, smoking status, BMI, prior insulin use, total serum cholesterol, previous stroke, previous TIA